Literature DB >> 3052322

The first international standard for antibodies to double stranded DNA.

T E Feltkamp1, T B Kirkwood, R N Maini, L A Aarden.   

Abstract

This paper announces the availability of the first international standard for anti-double-stranded DNA (anti-dsDNA). The material, coded Wo/80, was obtained after recalcification of plasma taken from a patient with systemic lupus erythematosus. Vials were filled with 500 microliters serum and freeze dried. The serum contains no other autoantibodies in measurable quantities. The vials should be stored at -20 degrees C. The standard should be used for establishing national, regional, or local standards. In eight laboratories satisfactory results with the immunofluorescence technique on Crithidia luciliae were obtained; the titres varied between 1/20 and 1/640 (mean 1/160). In seven laboratories the Farr assay, with the so called 'Amersham kit', was performed. At a dilution of 1:40 a mean binding percentage of about 50% was observed. After reconstitution with 500 microliters of distilled water, the vial contains 100 IU/500 microliters or 200 IU/ml. The standard can be obtained from the custodian of WHO: Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, PO Box 9190 1006 AD Amsterdam, The Netherlands.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3052322      PMCID: PMC1003590          DOI: 10.1136/ard.47.9.740

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  2 in total

1.  A DNA-reacting factor in serum of a patient with lupus erythematosus diffusus.

Authors:  R CEPPELLINI; E POLLI; F CELADA
Journal:  Proc Soc Exp Biol Med       Date:  1957-12

2.  Design and analysis of accelerated degradation tests for the stability of biological standards I. Properties of maximum likelihood estimators.

Authors:  M S Tydeman; T B Kirkwood
Journal:  J Biol Stand       Date:  1984
  2 in total
  16 in total

1.  Anti-double-stranded DNA antibodies in the healthy elderly: prevalence and characteristics.

Authors:  A Ruffatti; A Calligaro; T Del Ross; M T Bertoli; A Doria; L Rossi; S Todesco
Journal:  J Clin Immunol       Date:  1990-11       Impact factor: 8.317

2.  Lack of specificity for antibodies to double stranded DNA found in four commercial kits.

Authors:  M Kadlubowski; M Jackson; P L Yap; G Neill
Journal:  J Clin Pathol       Date:  1991-03       Impact factor: 3.411

3.  Standards for ANA and anti-DNA.

Authors:  T E Feltkamp
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

4.  Anti-CD3-induced and anti-Fas-induced apoptosis in systemic lupus erythematosus (SLE).

Authors:  M Bijl; G Horst; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

5.  Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4 and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus: a prospective study.

Authors:  P E Spronk; E J ter Borg; M G Huitema; P C Limburg; C G Kallenberg
Journal:  Ann Rheum Dis       Date:  1994-04       Impact factor: 19.103

6.  Clinical evaluation of cobas core anti-dsDNA EIA quant.

Authors:  Concepción González; Paloma Guevara; Belén García-Berrocal; José Alejandro Navajo; José Manuel González-Buitrago
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

7.  Detection of antibodies to DNA: a technical assessment.

Authors:  R Smeenk; M Hylkema
Journal:  Mol Biol Rep       Date:  1992-11       Impact factor: 2.316

Review 8.  Anti-dsDNA: choice of assay in relation to clinical value.

Authors:  R J Smeenk; H G van den Brink; K Brinkman; R M Termaat; J H Berden; A J Swaak
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

9.  Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk.

Authors:  M Bijl; G Horst; H Bootsma; P C Limburg; C G M Kallenberg
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

10.  Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity?

Authors:  P E Spronk; E J ter Borg; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.